IRWD

#2732
Ironwood Pharmaceuticals, Inc. - Class A
4.03 USD
+10.41%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
3.98
4.03
1年のレンジ
0.53
5.78
1日の変化
+10.41%
月次変化
+17.15%
6か月変化
+161.69%
1年の変化
+560.66%
以前の終値
3.65
始値
4.03
Bid
Ask
安値
3.98
High
4.03
ボリューム
246
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 657.13 M
  • Employee 100
  • Founded 1998
  • CEO N/A
  • Website www.ironwoodpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000GBZ3J2
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
22.47
売上高対価格比率
1.85

Ironwood Pharmaceuticals Inc - Class A

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. By 2004 the company had raised $99M and was preparing a Phase I trial for linaclotide.

ニュース